Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 12/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.45 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13009516 | 0.88 | DGAT1 (0.46) | JAK2DGAT1CYP3A4SOAT1DEGS1 | |
| SCHEMBL3538892 | 0.85 | MAPT (0.47) | DGAT1KDM4EMAPTKCNH2MCHR1 | |
| SCHEMBL3543293 | 0.80 | KDM4E (0.52) | DGAT1KDM4EMAPTRAB9AL3MBTL1 | |
| SCHEMBL3545445 | 0.79 | DHODH (0.39) | DGAT1CYP3A4KDM4E | |
| SCHEMBL3540578 | 0.79 | DGAT1 (0.44) | DGAT1SOAT1KDM4E | |
| SCHEMBL3540582 | 0.79 | DGAT1 (0.44) | DGAT1SOAT1KDM4E | |
| SCHEMBL3537299 | 0.79 | DGAT1 (0.49) | DGAT1CYP3A4SOAT1ACAT1DEGS1 | |
| SCHEMBL3541406 | 0.78 | DGAT1 (0.57) | DGAT1KDM4EL3MBTL1 | |
| SCHEMBL4500215 | 0.78 | MAPT (0.61) | DGAT1MAPTRAB9A | |
| SCHEMBL3542683 | 0.78 | DGAT1 (0.48) | SYKJAK2DGAT1DEGS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | SYK 3890/4885JAK2 2560/4885DGAT1 1/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | SYK 4010/4885JAK2 2557/4885DGAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.